Phase I Safety Profile: While topical and low-dose injectable formulations demonstrate high tolerance and minimal systemic toxicity, there is no formal Phase I safety data for chronic 85 mg/day intranasal delivery in humans
Visible body composition changes, including fat loss and lean muscle definition, become apparent between weeks 6 and 12
To achieve these objectives, the study combined several methodological approaches
As a result, these agents act together to cause additional oxidative damage, creating a never-ending chain reaction (also may be considered a feed-forward loop)
Supports liver health and function: Essential for phase II liver detoxification, Glutathione assists in processing and eliminating waste products efficiently
Decreased GSH levels and impaired GSH synthesis and recycling have been observed in aging, suggesting a potential therapeutic target for restoring redox balance and mitigating oxidative damage